Perspective Therapeutics (CATX) Income towards Parent Company (2016 - 2026)
Perspective Therapeutics' Income towards Parent Company history spans 17 years, with the latest figure at -$26.2 million for Q1 2026.
- On a quarterly basis, Income towards Parent Company changed N/A to -$26.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$25.7 million, a 5139.8% decrease, with the full-year FY2025 number at $514000.0, up 154.16% from a year prior.
- Income towards Parent Company hit -$26.2 million in Q1 2026 for Perspective Therapeutics, down from $514000.0 in the prior quarter.
- Over the last five years, Income towards Parent Company for CATX hit a ceiling of $514000.0 in Q2 2025 and a floor of -$26.2 million in Q1 2026.
- Historically, Income towards Parent Company has averaged -$3.8 million across 5 years, with a median of -$1.5 million in 2023.
- Biggest five-year swings in Income towards Parent Company: tumbled 254.38% in 2022 and later skyrocketed 204.9% in 2025.
- Tracing CATX's Income towards Parent Company over 5 years: stood at -$2.3 million in 2022, then plummeted by 127.82% to -$5.2 million in 2023, then surged by 90.55% to -$490000.0 in 2024, then skyrocketed by 204.9% to $514000.0 in 2025, then plummeted by 5195.14% to -$26.2 million in 2026.
- Business Quant data shows Income towards Parent Company for CATX at -$26.2 million in Q1 2026, $514000.0 in Q2 2025, and -$490000.0 in Q2 2024.